XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome.
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this trial is to assess the long-term safety and efficacy of XP13512
(Gabapentin Enacarbil) taken once daily for the treatment of patients suffering from Restless
Legs Syndrome (RLS).